First post-integration order lands, validating WuXi XDC's antibody intermediate development and manufacturing capabilities

Overview

This report comments on WuXi XDC Cayman Inc. (2268.HK)'s mAb intermediate process development and manufacturing services agreement related to BioDlink. After WuXi XDC completed the acquisition of a 60% stake in BioDlink at the end of March 2026, BioDlink will supply 10 batches of mAb intermediates to WuXi Bio for a contract value of Rmb19mn. Morgan Stanley views this as the first validating order after integration, believing it proves BioDlink's development and manufacturing capabilities can meet WuXi XDC's standards and aligns with the company's strategy to expand capacity and improve end-to-end self-sufficiency.

Core views

The core view is that, amid rising bioconjugation demand and order backlog growth, WuXi XDC needs to expand capacity ahead of time to capture commercial-scale contracts. BioDlink's antibody and ADC capacity, the expected GMP release of its Singapore base, the Hefei peptide/oligonucleotide base, and the construction of payload-linker capacity in Jiangyin all help fill out WuXi XDC's capabilities from antibody procurement to full self-sufficient production. The report remains positive on the company, emphasizing that order growth, later-stage project volume, and higher utilization of the Singapore facility could provide upside.

Analysis framework

The report adopts an event-driven analysis, combining BioDlink's first service agreement with WuXi XDC's acquisition rationale, capacity planning, commercial contract readiness, and DCF valuation framework. It focuses on whether the order can prove integration capability, whether capacity expansion can support revenue growth, and the impact of higher utilization at new facilities on margin improvement.

Methodology notes

• Valuation methodsDCF

  discounted cash flow valuation

  The target price is based on a DCF method, suitable for a CDMO company in a growth cycle; the report assumes a WACC of 10%, a perpetual growth rate of 5%, and HKD/RMB of 0.92.

• ratingMorgan Stanley relative rating system

  Overweight / Attractive

  Overweight means the stock's total return over the next 12-18 months is expected to outperform the analyst coverage universe on a risk-adjusted basis; Attractive means the industry is expected to be attractive relative to the relevant broad-market benchmark over the next 12-18 months.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi XDC Cayman Inc. (2268.HK)

  The report's subject; an ADC/CDMO platform directly affected by BioDlink integration and capacity expansion.

  Strengths

  First post-integration order from BioDlink; antibody, ADC, Singapore, Hefei, and Jiangyin bases collectively strengthen the capacity layout; the company guides for more than 35% revenue growth in 2026.

  Weaknesses

  Still in the capacity expansion and integration phase; commercial-scale orders, facility utilization, and margin improvement still need to be realized in future periods.

  Comparison

  Compared with a typical CDMO company, the report highlights WuXi XDC's medium- to long-term growth potential driven by bioconjugation demand, capacity expansion, and end-to-end self-sufficiency.

  Risks

  A slowdown in biotech financing and pipeline progress, weaker-than-expected later-stage and commercial contract sales, and margin improvement at new facilities that falls short of expectations.

• WuXi Biologics Cayman Inc. (2269.HK)

  WuXi XDC's current source of antibody procurement and the counterparty to WuXi Bio contracts, with BioDlink supplying mAb intermediates to it.

  Strengths

  As the parent/affiliate company, it can provide antibody supply and order synergy to WuXi XDC.

  Weaknesses

  WuXi XDC is still procuring antibodies, and full self-sufficiency has yet to be achieved until the expansion plan is completed.

  Comparison

  Compared with WuXi XDC, WuXi Bio is more focused on upstream biopharma CDMO, while the report remains focused on WuXi XDC's bioconjugation and ADC chain.

  Risks

  There is execution uncertainty around related-party collaboration, supply arrangements, and the pace of WuXi XDC's transition to self-sufficiency.

• WuXi AppTec Co Ltd (603259.SS / 2359.HK)

  A related WuXi Group company mentioned in the disclosure and valuation assumptions; the WACC assumption is consistent with WuXi AppTec's framework.

  Strengths

  The WuXi platform has an industrial chain synergy backdrop in the pharmaceutical outsourcing sector.

  Weaknesses

  This report is not centered on WuXi AppTec and does not provide an event-driven investment conclusion for 603259.SS.

  Comparison

  WuXi AppTec is a more comprehensive pharmaceutical R&D services platform, while WuXi XDC focuses on ADC and bioconjugation CDMO.

  Risks

  WuXi Group companies collectively face risks related to industry cyclicality, financing conditions, and regulatory disclosure.

Key data

• BioDlink equity acquisition60%WuXi XDC completed the acquisition of a 60% stake in BioDlink at the end of March 2026.
• mAb intermediate order10 batches, Rmb19mnBioDlink will supply 10 batches of mAb intermediates to WuXi Bio, with the agreement valid until December 31, 2026.
• production equipment50L / 200L / 500L pilot-scale bioreactorsCorresponding pilot-scale bioreactors are used according to per-batch output requirements.
• service scopeprocess development/technology transfer, upstream cell expansion, downstream purification, bulk DS filing, etc.The order covers key development and manufacturing steps in mAb intermediate production.
• WuXi XDC drug product capacity targetdouble drug product capacity by 2029; 19 million vials by end-2025The company is expanding capacity ahead of commercial-scale contracts.
• BioDlink antibody capacity30 million vials/year, supported by 300,000L DS capacityOne of the capacity foundations brought by the BioDlink acquisition.
• BioDlink ADC capacity5.3 million vials/year, supported by 960kg DS capacitySupports the expansion of WuXi XDC's ADC CDMO capabilities.
• Singapore base incremental capacityexpected incremental 8 million vialsThe Singapore base is expected to receive GMP release in the summer.
• 2026 revenue guidance>35% growthThe report cites the company's revenue growth guidance for 2026.
• 2026 capital expenditureRmb3.1bnThe report cites the company's 2026 capex guidance.
• target priceHK$83.00WuXi XDC target price given by Morgan Stanley.
• current priceHK$46.70Price for WuXi XDC Cayman Inc. (2268.HK) in the disclosure table as of 06/18/2026.

Impact & implications

The main significance of this event for WuXi XDC is that it validates BioDlink's ability to provide development and manufacturing services that meet group standards after integration, while also providing the capacity base for the company to transition from relying on WuXi Bio for antibody procurement to end-to-end self-sufficiency. If subsequent orders, GMP release, and new-facility utilization progress as planned, the visibility of the company's medium- to long-term revenue growth and margin improvement logic will increase; otherwise, if commercial contract conversion or facility utilization falls short of expectations, valuation and earnings upside may be constrained.

Risks

• A slowdown in biotech financing and a deceleration in pipeline progress may affect order demand.
• Later-stage project and commercial contract sales may be weaker than expected.
• A slow ramp-up in new facilities such as Singapore may lead to margin improvement below expectations.
• BioDlink integration, technology transfer, and capacity release involve execution risks.
• A slower-than-expected rollout of commercial-scale contracts may weaken the return on expansion.
• Morgan Stanley disclosed that it has investment banking and other service relationships with covered companies, and investors should note the potential conflict of interest.

What to watch

• BioDlink order execution progress and follow-on new orders.
• GMP release timing for the Singapore base and the release of the additional 8 million vials of capacity.
• Progress toward WuXi XDC's target to double drug product capacity by 2029.
• Construction progress of the Hefei peptide/oligonucleotide base and the Jiangyin payload-linker base.
• Delivery on the 2026 guidance of more than 35% revenue growth and Rmb3.1bn in capex.
• Conversion of later-stage projects and commercial contracts, and the impact of new-facility utilization on margins.